Benitec Biopharma Inc
BNTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$303.42M
Close$
$2.68
74.3% downside
Current Fair Value
74.3% downsideOvervalued by 74.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $303.42 Million |
|---|---|
| Enterprise Value | $119.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.05 |
| Beta | 0.28 |
| Outstanding Shares | 49,386,203 |
Return
| Return on Equity | -26.66% |
|---|---|
| Return on Assets | -26.14% |
| Return on Invested Capital | -30.22% |
Valuation & Multiples
| P/E Ratio | -11.68 |
|---|---|
| PEG | -42.33 |
| Price to Sales | - |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 214.98 |
| Enterprise Value to EBIT | -2.15 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 28, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.46%▲ 1.59% |
|---|---|
| Total Invested | $345.07M▼ 19.11% |
| Investors Holding | 88▲ 17.00% |
ESG Score
No data